This is a working overview of HGF mimetic, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-20. Anything still debated is marked as such rather than presented as settled.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Primary reported target | Hepatocyte growth factor/c-Met signaling | Findings mainly from cell and animal studies. |
| Related endogenous peptide | Angiotensin IV | Dihexa is described as a stabilized analog. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for purity assessment. |
| Identity confirmation | Mass spectrometry | Provides a molecular mass check. |
| Regulatory status | Not approved for human use | Sold as a research chemical in many jurisdictions. |
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
In April 1927, Chiang Kai-shek purged the communists in the Shanghai Massacre, causing the collapse of the First United Front and the split within the Nationalists between the Nanjing and Wuhan governments. Despite his past alliances of convenience with progressives, Liu Wenhui joined with every other major Sichuan warlord to issue a joint telegram, declaring the orders of the Wuhan government "invalid." Later that year, he made a secret pact with fellow Baoding officers Tian Songyao and Deng Xihou, wherein Liu would support Deng and Tian in an offensive to take control of Chongqing, and the two would support Liu in his campaign to take over Xikang from Liu Chengxun. The planned offensive against Chongqing did not happen.
=== Trials of procedures === Similarly to drugs, medical or surgical procedures may be subjected to clinical trials, such as comparing different surgical approaches in treatment of fibroids for subfertility. However, when clinical trials are unethical or logistically impossible in the surgical setting, case-controlled studies will be replaced.
== Chemistry == Retatrutide is a peptide with the following amino acid sequence YA¹QGTFTSDYSIL²LDKK⁴AQA¹AFIEYLLEGGPSSGAPPPS³ where letters with superscripted numbers refer to the following chemical modifications:
Sources: en.wikipedia.org
== Cytosolic Fatty Acid Synthesis == While essential fatty acids (i.e., linoleic acid) are obtained exclusively through diet, all non-essential fatty acids must be synthesized de novo. Acetyl-CoA is the precursor used for fatty acid synthesis in the cytosol; therefore, fatty acid synthesis requires those reactions which produce acetyl-CoA—namely, glycolysis or amino acid metabolism. Regardless of the metabolic source of the product, all de novo lipogenesis relies on the production and availability of cytosolic acetyl-CoA, and thereafter on its conversion into malonyl-CoA.
FAPLA's Cuban allies were less optimistic: they noted that the brigades were isolated, incapable of reinforcing each other quickly, and possessed insufficient mobile anti-aircraft weapons to protect them outside their bases. The Soviets recommended a static defence, appealing directly to Angolan President José Eduardo dos Santos, while the Cubans urged a withdrawal. Caught between two conflicting recommendations, dos Santos hesitated, and the brigades were ultimately annihilated piecemeal by the advancing South African armoured columns. Amid the confusion, a number of Angolan troops managed to break out of the South African encirclement and move north to link up with Cuban units, but a total of 471 FAPLA/PLAN personnel were killed or captured. Despite achieving their objectives during Operation Askari, the South African forces had encountered unexpectedly determined resistance from PLAN and FAPLA. The SADF acknowledged 25 killed in action and 94 wounded, the highest number of casualties suffered in any single operation since Operation Savannah. FAPLA also claimed to have shot down 4 South African aircraft.
Hookah, Sasuba and Snuba systems are categorised as "air-line" equipment, as they do not include the communication, lifeline and pneumofathometer hose characteristic of a full diver's umbilical. Most hookah diving uses a demand system based on a standard scuba second stage, but there have been special purpose free-flow full-face masks specifically intended for hookah diving (see photos). A bailout system, or emergency gas supply (EGS) is not an inherent part of an air-line diving system, though it may be required in some applications. Their field of application is very different from full surface-supplied diving. Hookah is generally used for shallow water work in low-hazard applications, such as archaeology, aquaculture, and aquarium maintenance work, but is also sometimes used for open water hunting and gathering of seafood, shallow water mining of gold and diamonds in rivers and streams, and bottom cleaning and other underwater maintenance of boats. Sasuba and Snuba are mainly a shallow water recreational application for low-hazard sites. Sasuba and hookah diving equipment is also used for boat maintenance and hull cleaning, swimming pool maintenance, and shallow underwater inspections. The systems used to supply air through the hose to a demand valve mouthpiece, are either 12-volt electrical air pumps, gasoline engine powered low-pressure compressors, or floating scuba cylinders with high pressure regulators. These hookah diving systems usually limit the hose length to allow less than 7 metres depth.
Sources: en.wikipedia.org
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.
Reverse-phase high-performance liquid chromatography is commonly used to assess purity. Mass spectrometry is used to confirm molecular identity. These methods are typical for synthetic peptides and research chemicals.
Dihexa is not approved as a drug in major jurisdictions. It is often sold as a research chemical, which is not the same as a medicine. Its legal status can vary by country and may change.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.